Navigation Links
Frost & Sullivan Says, Innovative Therapies Needed to Deal With the Rapid Spread of Cancer in Europe
Date:2/17/2009

LONDON, Feb. 17 /PRNewswire/ -- Cancer may well surpass cardiovascular diseases as the primary case of death in Europe by 2012. To prevent this from happening, cancer therapeutics have to shift in focus from the treatment of symptoms to offering a total cure, despite the complex, multifactorial nature of cancer indications.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"As cancer spreads rapidly through Europe, therapy developers are looking to improve the cancer treatment profile through technological advances in diagnosis and treatment," says an analyst from Frost & Sullivan (http://www.medicaldevices.frost.com). "Innovative approaches to cancer therapy will help address unmet medical needs as well as enable the prognosis of cancer indications."

Several cancer indications such as non-small cell lung cancer (NSCLC) are associated with very high mortality rates. This shows that intense technological improvements are needed to enhance the prognosis and treatment of major cancer indications.

Treatment developers should aim to keep pace with the growing demand for therapies that can improve patients' quality of life.

"Treatments with fewer side effects and that can reduce hospital stays are preferred over radical procedures such as surgery, wherever feasible," the analyst notes. "An increasing demand for minimally invasive or non-invasive alternatives to existing treatments such as chemotherapy and surgery is driving the growth of radiation therapy -- particularly in developed countries."

The trend toward multimodality deals, along with digitisation and price erosion are expected to drive consolidation in the cancer therapy market. The healthcare market in Europe is cost constrained and the purse strings are likely to tighten further with governments planning to implement several cost-containment measures.

"Budgets for hospitals are being reduced, leading to an increase in tendering arrangements between hospitals and companies, to reduce prices," observes the analyst. "This could result in the reluctance of physicians to use adjuvant therapy or prescribe more expensive therapies, which do not offer significant survival benefits."

While these policies compel companies to keep their prices low, extensive publicity about cancer mortality rates has ensured that there is adequate focus on cancer research. Many public research organisations and associations have been contributing substantially towards cancer treatment research programmes, keeping the market buoyant.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the issues; trends and prevalence in the European non-pharmaceutical cancer therapy market, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com. Please include your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

Issues; Trends and Prevalence in the European Cancer Therapy Market - Non Pharmaceutical is part of the Medical Devices Growth Partnership Service programme, which also includes research in the following markets: European urinary incontinence devices market, European tissue sealants and topical haemostats market, European bone growth and spinal fusion stimulators market and issues and trends in hospital-based infections across Europe. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan has expanded its flagship Global Congress on Corporate Growth -- GIL Global -- into several major cities around the world including London. For the first time ever in Europe, Frost & Sullivan will be hosting the Growth, Innovation and Leadership Congress 'GIL 2009: Europe' on 19-20 May, at the Sofitel St James in London. GIL Global is the industry's only event designed to support senior executives in their efforts to achieve sustainable, top-line growth. To register, obtain a programme agenda, explore sponsorship opportunities, or attend as a member of the media for GIL 2009: Europe, please contact Katja Feick, Corporate Communications Europe, at katja.feick@frost.com. One-on-One interviews with Frost & Sullivan senior growth consultants are also being scheduled. For more information you can also visit http://www.frost.com/giluk

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

  Issues; Trends and Prevalence in the European Cancer Therapy Market - Non
                                Pharmaceutical
                                    (M2CC)

     Contact:
     Katja Feick
     Corporate Communications - Europe
     P: +49 (0) 69 77 0 33 43
     E: katja.feick@frost.com
    http://www.frost.com

'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Frost & Sullivan Helps You Know Your End-Market: Medical Trends Impacting the Chemicals and Materials Markets
2. Frost & Sullivan - Consumer Preference for Healthy Bakery
3. Frost & Sullivan Finds Compliance Requirements Drive the Healthcare Security Boom
4. Frost & Sullivan Bestows Product Line Strategy Leadership Award to VTS Medical Systems, LLC
5. Frost & Sullivan Forecasts Increased Demand for Portable and PC-based Ultrasound Units in Eastern Europe
6. Verified Physicians a Must for Ensuring Quality Data From Online Surveys, Finds Frost & Sullivan
7. Ready-To-Use Products Spur the European Tissue Sealants and Topical Hemostats Markets, Says Frost & Sullivan
8. Frost & Sullivan to Host Analyst Briefing on the European Orphan Diseases Market: Niche-Busters - An Attractive Future?
9. VTS Medical Systems, LLC Awarded Frost & Sullivan Excellence in Healthcare, Product Line Strategy Leadership Award for 2009
10. Horphag Research Receives 2008 Frost & Sullivan North American Health Ingredients Excellence In Research Award
11. TECNIMED Picks Up Frost & Sullivan Award for its Innovative THERMOFOCUS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve their approach ... patient is doing more than filling out a survey; in many cases health professionals ... emphasis in health care and research on the importance of active engagement with patients ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
(Date:9/18/2017)... , Sept. 18, 2017  PMD Healthcare of ... Pharmacy of Kalamazoo, Mich. , have ... service that expedites and streamlines patient and provider access ... 2.0, and wellness management services.  ... used to measure lung function for a variety of ...
(Date:9/13/2017)... OrthoAtlanta has been named the official orthopedic and sports ... the 2018 College Football Playoff (CFP) National Championship to be ... Atlanta, Georgia . OrthoAtlanta is proud to ... in many activities leading up to, and including the national ... OrthoAtlanta ...
Breaking Medicine Technology: